Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC)

References

• Staines A, Cartwright RA. Hairy cell leukaemia: descriptive epidemiology and a case-control study. Br J Haematol 1993;85: 714–717.
   PubMed Web of Science ®Google Scholar
• Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011;364:2305–2315.
   PubMed Web of Science ®Google Scholar
• Cannon T, Mobarek D, Wegge J, et al. Hairy cell leukemia: current concepts. Cancer Invest 2008;26:860–865.
   PubMed Web of Science ®Google Scholar
• Berman E, Heller G, Kempin S, et al. Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a. Blood 1990;75:839–845.
   PubMed Web of Science ®Google Scholar
• Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 1995;13: 974–982.
   PubMed Web of Science ®Google Scholar
• Federico M, Frassoldati A, Lamparelli T, et al. Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooperative Group for HCL. Ann Oncol 1994;5:725–731.
   PubMed Web of Science ®Google Scholar
• Chadha P, Rademaker AW, Mendiratta P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood 2005;106:241–246.
   PubMed Web of Science ®Google Scholar
• Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009;145:733–740.
   PubMed Web of Science ®Google Scholar
• Goodman GR, Burian C, Koziol JA, et al. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003;21:891–896.
   PubMed Web of Science ®Google Scholar
• Jehn U, Bartl R, Dietzfelbinger H, et al. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 2004;18:1476–1481.
   PubMed Web of Science ®Google Scholar
• Grever MR. How I treat hairy cell leukemia. Blood 2010;115: 21–28.
   PubMed Web of Science ®Google Scholar
• Benz R, Stussi G, Fehr J. Interferon as an alternative to purine analogues in the treatment of hairy cell leukaemia. Br J Haematol 2010;148:664–665.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Estey EH, Keating MJ, et al. Response to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine. Leukemia 1995;9:929–932.
   PubMed Web of Science ®Google Scholar
• Katayama I, Yang JP. Reassessment of a cytochemical test for differential diagnosis of leukemic reticuloendotheliosis. Am J Clin Pathol 1977;68:268–272.
   PubMed Web of Science ®Google Scholar
• Polliack A, Tadmor T. Surface topography of hairy cell leukemia cells compared to other leukemias as seen by scanning electron microscopy. Leuk Lymphoma 2011;52(Suppl. 2):14–17.
   PubMed Web of Science ®Google Scholar
• Consensus resolution: proposed criteria for evaluation of response to treatment in hairy cell leukaemia. Leukemia 1987;1:405.
   PubMed Web of Science ®Google Scholar
• Maloisel F, Benboubker L, Gardembas M, et al. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia 2003;17:45–51.
   PubMed Web of Science ®Google Scholar
• Saven A, Burian C, Koziol JA, et al. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998;92:1918–1926.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Kopecky KJ, Foucar MK, et al. Long-term follow- up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 2000; 96:2981–2986.
   PubMed Web of Science ®Google Scholar
• Rafel M, Cervantes F, Beltran JM, et al. Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients. Cancer 2000;88:352–357.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Tani M, Marchi E, et al. Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Haematologica 2004;89:309–313.
   PubMed Web of Science ®Google Scholar
• Jehn U, Bartl R, Dietzfelbinger H, et al. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 2004;18:1476–1481.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Hakimian D, Rademaker AW, et al. Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. Blood 1996;88:1954–1959.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Sorensen JM, Vena DA, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998;16:3007–3015.
   PubMed Web of Science ®Google Scholar
• Jansen J, Hermans J. Clinical staging system for hairy-cell leukemia. Blood 1982;60:571–577.
   PubMed Web of Science ®Google Scholar
• Ellison DJ, Sharpe RW, Robbins BA, et al. Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 1994;84:4310–4315.
   PubMed Web of Science ®Google Scholar
• Matutes E, Meeus P, McLennan K, et al. The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: a long-term follow-up study. Br J Haematol 1997;98:375–383.
   PubMed Web of Science ®Google Scholar
• Bengio R, Narbaitz MI, Sarmiento MA, et al. Comparative analysis of immunophenotypic methods for the assessment of minimal residual disease in hairy cell leukemia. Haematologica 2000;85:1227–1229.
   PubMed Web of Science ®Google Scholar
• Sausville JE, Salloum RG, Sorbara L, et al. Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene. Am J Clin Pathol 2003;119:213–217.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Hakimian D, Kopecky KJ, et al. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse. Clin Cancer Res 1999;5:1665–1670.
   PubMed Web of Science ®Google Scholar
• Wheaton S, Tallman MS, Hakimian D, et al. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood 1996;87: 1556–1560.
   PubMed Web of Science ®Google Scholar